Baseline characteristics of the combined UIC and VUMC cohorts of adults with SCD
| Variable . | UIC & VUMC cohorts of adults with SCD N = 379 . |
|---|---|
| Age, y | 33.0 (25.8-44.1) |
| Female sex | 209 (55.1%) |
| SCD genotype | |
| Hemoglobin SS or Sβ0-thalassemia | 285 (75.2%) |
| Hemoglobin SC | 66 (17.4%) |
| Hemoglobin Sβ+-thalassemia | 28 (7.4%) |
| Hydroxyurea use | 204 (53.8%) |
| RAASi use | 75 (19.8%) |
| ACE inhibitors | 58 (15.3%) |
| ARBs | 17 (4.5%) |
| Chronic RBC transfusions | 30 (7.9%) |
| Body mass index, kg/m2 | 24.3 (21.5-28.4) |
| Systolic blood pressure, mmHg | 118 (109-129) |
| WBC count (× 103/μL) | 9.4 (7.0-12.0) |
| Hemoglobin, g/dL | 9.3 (8.2-10.5) |
| Platelet count (× 103/μL) | 358 (262-450) |
| Hemoglobin F, % | 7.5 (3.5-13.65) |
| Reticulocyte, % | 8.7 (4.5-12.9) |
| LDH, U/L | 320 (244-460) |
| UACR, mg/g | 27 (10-117) |
| UACR category, mg/g of creatinine | |
| Normal (<30) | 232 (61.2%) |
| Moderately elevated (30-300) | 104 (27.4%) |
| Severely elevated (>300) | 43 (11.3%) |
| eGFR, mL/min per 1.73 m2 | 120 (101-133) |
| eGFR category, mL/min per 1.73 m2 | |
| G1 (>90) | 317 (83.6%) |
| G2 (60-89) | 43 (11.3%) |
| G3a (45-59) | 10 (2.6%) |
| G3b (30-44) | 5 (1.3%) |
| G4 (15-29) | 3 (0.8%) |
| G5 (<15) | 1 (0.3%) |
| Variable . | UIC & VUMC cohorts of adults with SCD N = 379 . |
|---|---|
| Age, y | 33.0 (25.8-44.1) |
| Female sex | 209 (55.1%) |
| SCD genotype | |
| Hemoglobin SS or Sβ0-thalassemia | 285 (75.2%) |
| Hemoglobin SC | 66 (17.4%) |
| Hemoglobin Sβ+-thalassemia | 28 (7.4%) |
| Hydroxyurea use | 204 (53.8%) |
| RAASi use | 75 (19.8%) |
| ACE inhibitors | 58 (15.3%) |
| ARBs | 17 (4.5%) |
| Chronic RBC transfusions | 30 (7.9%) |
| Body mass index, kg/m2 | 24.3 (21.5-28.4) |
| Systolic blood pressure, mmHg | 118 (109-129) |
| WBC count (× 103/μL) | 9.4 (7.0-12.0) |
| Hemoglobin, g/dL | 9.3 (8.2-10.5) |
| Platelet count (× 103/μL) | 358 (262-450) |
| Hemoglobin F, % | 7.5 (3.5-13.65) |
| Reticulocyte, % | 8.7 (4.5-12.9) |
| LDH, U/L | 320 (244-460) |
| UACR, mg/g | 27 (10-117) |
| UACR category, mg/g of creatinine | |
| Normal (<30) | 232 (61.2%) |
| Moderately elevated (30-300) | 104 (27.4%) |
| Severely elevated (>300) | 43 (11.3%) |
| eGFR, mL/min per 1.73 m2 | 120 (101-133) |
| eGFR category, mL/min per 1.73 m2 | |
| G1 (>90) | 317 (83.6%) |
| G2 (60-89) | 43 (11.3%) |
| G3a (45-59) | 10 (2.6%) |
| G3b (30-44) | 5 (1.3%) |
| G4 (15-29) | 3 (0.8%) |
| G5 (<15) | 1 (0.3%) |
Data are presented as median (interquartile values) and frequency (%).
ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blocker; LDH, lactate dehydrogenase; RBC, red blood cell; UIC, University of Illinois Chicago; VUMC, Vanderbilt University Medical Center; WBC, white blood cell.